Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumour (GIST): North American intergroup phase III trial ACOSOG Z9001. ASCO Annual Meetings Proceedings Part I. - De Matteo,R.K.; Owzar,K.R.; Maki,R. (J Clin Oncol, 2007)